LICHTNER , M

Last name: LICHTNER

First name: M

2020 (v1)

Publication

Metadata-only

Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <=50 copies/ml: does eGFR matter?

Vergori, A Gagliardini, R Gianotti, N

No description

Uploaded on: April 14, 2023
2024 (v1)

Publication

Metadata-only

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

d'Arminio Monforte, Antonella Tavelli, Alessandro Di Biagio, Antonio

Objectives: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. Methods: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as...

Uploaded on: July 3, 2024
2024 (v1)

Publication

Metadata-only

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

d'Arminio Monforte, Antonella Tavelli, Alessandro Di Biagio, Antonio

Objectives: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. Methods: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as...

Uploaded on: July 3, 2024

LICHTNER , M

Recent uploads